Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Mark Bensink"'
Publikováno v:
Pain and Therapy, Vol 10, Iss 2, Pp 1551-1566 (2021)
Abstract Introduction Erenumab is indicated for migraine preventive treatment in adults. The objective of this study was to provide descriptive information on real-world use of erenumab including patient profile and treatment patterns. Methods We com
Externí odkaz:
https://doaj.org/article/f245ba570c2b441cad5f3c520991a92d
Publikováno v:
Pain and Therapy, Vol 12, Iss 3, Pp 889-889 (2023)
Externí odkaz:
https://doaj.org/article/e33a43bd37524d8dba7531eef5732027
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 5, Iss 1, Pp 1-13 (2021)
Abstract Background Several options for granulocyte colony-stimulating factor (G-CSF) prophylaxis of chemotherapy-induced febrile neutropenia are available to patients worldwide. We have developed a novel patient-reported outcome measure, the Satisfa
Externí odkaz:
https://doaj.org/article/41ff44655bfb42f285232d082622f1d5
Autor:
Derek Weycker, Robin Doroff, Ahuva Hanau, Charles Bowers, Rajesh Belani, David Chandler, Alexander Lonshteyn, Mark Bensink, Gary H. Lyman
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend routine prophylactic coverage with granulocyte colony-stimulating factor (G-CSF)—such as pegfilgrastim
Externí odkaz:
https://doaj.org/article/6f502dc328e549b0b73c5ea112ad8eb4
Autor:
Alina Bogdanov, Victoria Chia, Mark Bensink, Robert Urman, Lauren Fischer, Soeren Rasmussen, Christine Szekely, Lee Kallenbach
Publikováno v:
Cephalalgia Reports, Vol 4 (2021)
Background: Erenumab, a monoclonal antibody (mAb) developed to block the calcitonin gene-related peptide (CGRP) receptor, is approved for the prevention of migraine in adults. This retrospective observational study sought to describe early real-world
Externí odkaz:
https://doaj.org/article/399e71b34cba4ef3a41ce38049b9cb40
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234021 (2020)
[This corrects the article DOI: 10.1371/journal.pone.0138369.].
Externí odkaz:
https://doaj.org/article/112ce12e7cc94ce79c1bf03bc7c64f4b
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138369 (2015)
Indigenous Australians experience a high rate of ear disease and hearing loss, yet they have a lower rate of service access and utilisation compared to their non-Indigenous counterparts. Screening, surveillance and timely access to specialist ear, no
Externí odkaz:
https://doaj.org/article/0b88dc11ef57412fa3ed0ef5e4a5fef2
Autor:
Ariane K, Kawata, Mary Kate, Ladd, Richard B, Lipton, Dawn C, Buse, Mark, Bensink, Shweta, Shah, Asha, Hareendran, Sally, Mannix, Daniel, Mikol
Publikováno v:
Headache: The Journal of Head and Face Pain. 62:159-168
The purpose of this study was to examine changes in the functional impact of migraine following treatment with erenumab, as measured by the Migraine Functional Impact Questionnaire (MFIQ).The MFIQ, a novel patient-reported outcome (PRO) measuring the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1614d3e4924d11344c8673eb6410fea5
https://doi.org/10.1111/head.14258
https://doi.org/10.1111/head.14258
Publikováno v:
Pain and Therapy
Introduction Erenumab is indicated for migraine preventive treatment in adults. The objective of this study was to provide descriptive information on real-world use of erenumab including patient profile and treatment patterns. Methods We completed a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fc08f58e8f7ea46ca101d8f33ab4b18
https://doi.org/10.1007/s40122-021-00319-z
https://doi.org/10.1007/s40122-021-00319-z
Autor:
Apryl Quillen, Kim McLeod, Shweta Shah, Mark Bensink, Neel Shah, Carrie Dougherty, Fawad Khan, Jessica Ailani, Pooja Desai, Andrew Rubin
Publikováno v:
The Journal for Nurse Practitioners. 17:462-470
Objective This study was conducted to understand the impact of tracking migraine via an app on patient-provider communication and migraine outcomes as well as patient perspectives of the app. Methods Data collected were (1) patient-reported via a sma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4277c35980ad71d5de2e5d4b83a6df74
https://doi.org/10.1016/j.nurpra.2021.01.014
https://doi.org/10.1016/j.nurpra.2021.01.014